Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     

    If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

     Contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1620: Male and Female Participants with Nasal Polyps

    Research Purpose: Study 1620 is designed to determine the safety and tolerability of an investigational drug being developed for the treatment of Chronic Rhinosinusitis with Nasal Polyps.

    *Must be diagnosed with Nasal Polyps to participate in this study*


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women may participate if they meet one of the following criteria: postmenopausal, hysterectomy and/or bilateral oophorectomy, medically confirmed ovarian failure, tubal ligation or bilateral salpingectomy.

    Age

    18-65 years

    Body Mass Index (BMI)

    Between 17.5 – 35.0 kg/m²

    Tobacco/Nicotine Use

    Must be willing to abstain from tobacco and/or nicotine containing products for 24 hours prior to dosing and during the clinic stay.

    Health History

    Must be healthy; with the exception of diagnosed nasal polyps and chronic rhinosinusitis.

    Restricted Medications

    All medications will be reviewed for inclusion prior to screening.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 months.

    Clinic Stay

    • Participants will admit to Prism Clinical Research one-time for 2 overnights

    Clinic Visits

    • There are up to 13 follow-up clinical visits

     

    Compensation for participation time:   Up to $1,860                           


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1613 Part 2: Healthy Female and Male Participants

     

    Study 1613 Part 2: Healthy Female and Male Participants

     

    Research Purpose: To evaluate the safety and tolerability of an investigational drug being developed for the treatment of peanut allergy.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women on hormonal birth control are allowed to participate provided they use an approved secondary method of birth control.

    Age

    18-45 years

    Weight/Body Mass Index (BMI)

    Weight between 88 – 198 lbs. for women and between 110 – 220 lbs. for men. 

    BMI between 18-30 kg/m²

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes more frequently than 5 cigarettes per day prior to the study is allowed.  No tobacco/nicotine use is permitted for the duration of the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

     

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks with 2 follow-up phone questionnaires 6 months apart.

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time.
    • The in Clinic stay will last approximately 9 days (8 overnights)

    Outpatient Visits

    • There are 21 clinic visits following the discharge from the clinic.
    • End of study will be Day 35.
    • There will be 2 follow-up telephone questionnaires that will be performed approximately 6 months apart after completion of the clinic visits.

     

    Compensation for participation time: Up to $4695.00

     

    For information regarding this study contact Lindsay at 651-368-3360 or lindsayd@prismresearchinc.com

Glossary of Terms

  • Clinical Trial/Study: Any investigation in human subjects intended to discover or verify the clinical, pharmacological, and or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s) and/or to study absorption, distribution, metabolism and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical study are synonymous.

  • HIPAA: HIPAA is the acronym for the Health Insurance Portability and Accountability Act of 1996. The Centers for Medicare & Medicaid Services (CMS) is responsible for implementing various unrelated provisions of HIPAA. They are required to establish national standards for electronic health care transactions and national identifiers for providers, health plans, and employers. It also addresses the security and privacy of health data.

  • Informed Consent Form (ICF): A document approved by an authorized Institutional/Independent Review Board by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject’s decision to participate.

  • Informed Consent: A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject’s decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form.

  • Institutional/Independent Review Board (IRB): And independent body constituted of medical, scientific, and nonscientific members, whose responsibility it is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial by, among other things, reviewing, approving, and providing continuing review of trials, protocols, amendments, and methods and materials to be used in obtaining and documenting informed consent of the trial subjects.

  • Investigational Product: A pharmaceutical form of an active ingredient or placebo being tested or used as a reference n a clinical trial including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication or when used to gain further information about an approved use.

  • Investigator: A person responsible for the conduct of the clinical trial at the trial site. If a team of individuals at a trial site conducts a trial, the investigator is the responsible leader of the team and may be called the Principal Investigator.
  • Protocol: A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial.

  • Randomization: The process of assigning trial subjects to treatment or control groups using and element of chance to determine the assignments in order to reduce bias.

  • Sponsor: An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial.

  • Subject/Participant/Volunteer: An individual who participates in a clinical trial, either as a recipient of the investigational product(s) or as a control.

 

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel